AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7954550
Drug: Spironolactone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, 200 mg/day combined with furosemide, 40 mg on alternate days
Trial: 7954550
Drug: Torasemide, 10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide, 10-40 mg/day combined with spironolactone, 50-400 mg/day
Trial: 3661610
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g suspension four times daily for eight weeks
Trial: 3661610
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg four times daily for eight weeks
Trial: 29660190
Drug: HBAI20 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBAI20 vaccine
Trial: 12570120
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (200 microg twice daily)
Trial: 1382539
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg orally, 4 h before injection)
Trial: 3988974
Drug: Amitriptyline 150
RxNorm normalized name: amitriptyline 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 150 mg/day for 6 weeks
Trial: 29746294
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily Atripla regimen (OD)
Trial: 23924587
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (ADV) therapy
Trial: 18195173
Drug: Clopidogrel 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 0.20 mg/kg/day
Trial: 11092064
Drug: Nicotine 2‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2‐mg sublingual tablet
Trial: 1534211
Drug: Teicoplanin 3
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 3 mg/kg
Trial: 2149493
Drug: Teicoplanin 12
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 12 mg/kg
Trial: 1534211
Drug: Teicoplanin 30
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin 30 mg/kg
Trial: 1534211
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results of all doses (3, 12, 30 mg/kg)
Trial: 6330886
Drug: 28-day famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28-day famotidine treatment
Trial: 29800211
Drug: Fremanezumab monthly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab monthly dosing (225 mg at baseline, week 4, and week 8)
Trial: 29800211
Drug: Fremanezumab single
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab single higher dose (675 mg at baseline; placebo at weeks 4 and 8)
Trial: 26294680
Drug: Pilates-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates-based program twice a week for 6 weeks
Trial: 24478399
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during clamp
Trial: 24478399
Drug: Intralipid/heparin mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid/heparin mixture
Trial: 22441580
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for normal compliance (CON-NC)
Trial: 22441580
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for low compliance (CON-LC)
Trial: 17362728
Drug: Belzer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belzer solution
Trial: 8884833
Drug: Custodiol solution
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custodiol solution
Trial: 12271807
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) plus routine care
Trial: 8789468
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (COMB-HC)
Trial: 8789468
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (CABG-HC)
Trial: 1498296
Drug: Diltiazem (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.15 mg/kg bolus followed by 2 micrograms/kg/min)
Trial: 30667502
Drug: Low free
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low free sugar diet (restricted to less than 3% of daily calories for 8 weeks)
Trial: 27640607
Drug: naproxen plus
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen plus oxycodone/acetaminophen
Trial: 24528604
Drug: Assertive Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive Community Treatment (ACT) for elderly patients
Trial: 22920800
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin + recombinant human hyaluronidase (rHuPH20)
Trial: 22920800
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of rapid-acting insulin + rHuPH20
Trial: 22920800
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of rapid-acting insulin + rHuPH20
Trial: 21056840
Drug: Electro-acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture and behavior therapy
Trial: 21056840
Drug: Sham electro-acupuncture
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electro-acupuncture and behavior therapy
Trial: 10535857
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg + Vitamin E 100 mg twice daily
Trial: 8584522
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Fenoterol
Trial: 8584522
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg Salbutamol
Trial: 8584522
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg Salmeterol
Trial: 8584522
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medication (Salbutamol MDI)
Trial: 2338888
Drug: Naloxone (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.6 mg/h for 4 h)
Trial: 27960614
Drug: Long-term individual
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term individual shear rate therapy (ISRT)
Trial: 26578736
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 400 mg/day plus metformin 750-2250 mg/day for 24-36 weeks
Trial: 24948402
Drug: memantine (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine (maximal dose 20 mg/day)
Trial: 24948402
Drug: dextromethorphan (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextromethorphan (maximal dose 90 mg/day)
Trial: 19934286
Drug: CH4987655 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CH4987655 (0.5, 1, 2, 3, and 4 mg)
Trial: 18062141
Drug: Gardasil vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil vaccine
Trial: 11437394
Drug: High-dose IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IM Medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy during 6 months
Trial: 9544333
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injection with heparin sodium 10 units/mL
Trial: 9544333
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injection without heparin sodium
Trial: 29518178
Drug: Delafloxacin 300
RxNorm normalized name: delafloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 300 mg IV every 12 hours for 3 days followed by 450 mg oral delafloxacin
Trial: 29518178
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg IV with aztreonam for 5-14 days
Trial: 23749688
Drug: 8-week supervised
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week supervised aerobic exercise training (twice weekly)
Trial: 16862472
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous cephalothin 2 g, intraoperatively
Trial: 16862472
Drug: Standard antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotics scheme followed at this center (penicillin)
Trial: 9009151
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch therapy (group Q)
Trial: 9009151
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch therapy (group R)
Trial: 12518122
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (control group)
Trial: 30580198
Drug: Anxiolytics
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytics
Trial: 30445895
Drug: Higher antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher antipsychotic dosage at discharge
Trial: 20347286
Drug: Traditional exercise
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional exercise therapy (TET) program
Trial: 10342080
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (50 mg/m2 intramuscularly)
Trial: 8620703
Drug: Oral prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone, 50 mg (PRED)
Trial: 8620703
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate, 1,000 micrograms (F1000)
Trial: 8620703
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate, 2,000 micrograms (F2000)
Trial: 1835830
Drug: Dilute heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute heparin solution
Trial: 7343723
Drug: guanethidine/epinephrine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanethidine/epinephrine combination
Trial: 23426616
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (100 mg/kg/d for 4 weeks)
Trial: 19276620
Drug: both supplements
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both supplements (antioxidants and n-3 fatty acids)
Trial: 11782332
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil with epinephrine (100 microg/mL)
Trial: 7703623
Drug: MFP-calcium-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP-calcium-treated group (sodium monofluorophosphate 26 mg/day of fluoride + 1000 mg of calcium)
Trial: 1064725
Drug: Oxygel application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygel application and tooth brushing twice a day
Trial: 31392401
Drug: 28.2-μg twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28.2-μg twice-weekly teriparatide
Trial: 31392401
Drug: 56.5-μg once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56.5-μg once-weekly teriparatide
Trial: 25482330
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg once a day) plus peginterferon alfa‐2a and ribavirin
Trial: 25482330
Drug: Telaprevir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (750 mg three times a day) plus peginterferon alfa‐2a and ribavirin
Trial: 20137594
Drug: Xue Bijing
RxNorm normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xue Bijing injection, 100 ml intravenous once a day for 7 days
Trial: 20137594
Drug: Xue Bijing
RxNorm normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xue Bijing injection
Trial: 15228371
Drug: Preferred biologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred biologic therapy recommended for prior-authorization (PA) criteria
Trial: 15228371
Drug: Biologic agent
RxNorm normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agent with marginal incremental clinical benefit
Trial: 15228371
Drug: Biologic agent
RxNorm normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agent with increased efficacy
Trial: 15228371
Drug: Flexible PA
RxNorm normalized name: LIDOCAINE 40 mg in 1 g TOPICAL PATCH [Walgreens Flexible Pain Relieving Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible PA criteria for drug coverage
Trial: 11703235
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine with Hartmann's solution
Trial: 11703235
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Hartmann's solution without bupivacaine)
Trial: 9130221
Drug: 3% mepivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% mepivicaine (1.0 ml)
Trial: 8190448
Drug: Ampicillin-sulbactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam (3 g every 6 hours)
Trial: 8190448
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g every 6 hours) plus doxycycline (100 mg every 12 hours)
Trial: 8190448
Drug: Clindamycin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (900 mg every 8 hours) plus gentamicin (1.5 mg/kg every 8 hours)
Trial: 3370078
Drug: Piracetam 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 2400 mg
Trial: 30460634
Drug: 5-Azacytidine (5-AZA)
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-Azacytidine (5-AZA) 10 mg infusions, 12 consecutive weekly infusions planned
Trial: 27858681
Drug: Osteopathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manual therapy (OMT) and exercise methods
Trial: 27858681
Drug: Visceral osteopathic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visceral osteopathic manual therapy (vOMT)
Trial: 17909808
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg granular formulation of gefitinib
Trial: 17909808
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tablet of gefitinib
Trial: 10918945
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (benidipine)
Trial: 10918945
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor (trandolapril)
Trial: 6139191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyzine (10 mg qds) and cimetidine (400 mg qds)
Trial: 6139191
Drug: Other antihistamine
RxNorm normalized name: Other antihistamines for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihistamine regimes
Trial: 22406278
Drug: ProQuad(®) (MMRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 9 months
Trial: 22406278
Drug: ProQuad(®) (MMRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 11 months
Trial: 22406278
Drug: ProQuad(®) (MMRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 12 months
Trial: 22406278
Drug: ProQuad(®) (MMRV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProQuad(®) (MMRV vaccine) Dose 1 at 9 months, 11 months, or 12 months
Trial: 17916667
Drug: 6% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose beverage (1.00 g carbohydrate/kg body mass)
Trial: 3629428
Drug: Sputum cytologic
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum cytologic examinations (4-monthly)
Trial: 25976690
Drug: Arthrocentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis plus platelet-rich plasma (PRP) injection and then 4 consecutive PRP injections
Trial: 9834207
Drug: G-CSF treatment
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF treatment
Trial: 16556754
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave treatment (1500 impulses at 16 kV in a single session)
Trial: 14505915
Drug: Intranasal virosome
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal virosome vaccine adjuvanted with heat-labile toxin (HLT)
Trial: 14505915
Drug: Intranasal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccine without HLT
Trial: 8738052
Drug: Casodex 50
RxNorm normalized name: Casodex 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 50 mg monotherapy
Trial: 1582291
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg/ml)
Trial: 29249532
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (0.945 g/day, 64% ALA, 21% EPA, 16% DHA)
Trial: 22935844
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous L-carnitine after each dialysis session for 1 year
Trial: 12662379
Drug: N-acetyl cystein
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cystein (4%) 5 ml t.i.d. for 3 days (AC group, n = 53)
Trial: 9830877
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of social support and education
Trial: 2869573
Drug: Beta‐2 agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐2 agonist terbutaline (0.50 mg)
Trial: 2869573
Drug: Beta‐1 agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐1 agonist prenalterol (less than or equal to 5 mg)
Trial: 22365802
Drug: Acute low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute low dose tryptophan depletion (ATD)
Trial: 20569146
Drug: Oral PrEP
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PrEP for HIV prevention
Trial: 8602477
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (treatment for subacute low back pain)
Trial: 1974628
Drug: Ribavirin 800
RxNorm normalized name: ribavirin 800 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 800 mg
Trial: 1974628
Drug: Ribavirin 600
RxNorm normalized name: ribavirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 600 mg
Trial: 22958738
Drug: Standard CNI-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CNI-therapy
Trial: 19203529
Drug: Hutex omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hutex omeprazole (20 mg)
Trial: 19203529
Drug: Yuhan Losec
RxNorm normalized name: Losec
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yuhan Losec (20 mg)
Trial: 17970234
Drug: Intravenous rasburicase
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous rasburicase at a dose of 0.02 mg/kg/day for varying durations based on serum uric acid levels (3 days for 8-10 mg/dl, 5 days for 10-15 mg/dl, 7 days for >15 mg/dl)
Trial: 7774443
Drug: Combined operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined operative resection and immuno-chemotherapy (OIC)
Trial: 7774443
Drug: Combined operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined operative resection and immunotherapy (OI)